tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder
PPSTDCS-TOC
Direct Transcranial Stimulation With Direct Current Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive
1 other identifier
interventional
25
1 country
1
Brief Summary
This is a single-center study about patients with severe resistant OCD. Main assumption is that performing 10 tDCS sessions with the anode positioned at the level of the right orbitofrontal cortex, and the cathode at the level of the supplementary motor area, associated with the provocation of symptoms before each session is effective in the reduction in obsessive-compulsive symptoms. After the inclusion visit, the treatment period is provided from D1 to D12 (one session per day from Monday to Friday, for two consecutive weeks, i.e. a total of ten sessions). Each tDCS session lasts 30 minutes at an intensity of 2 mA and is preceded by symptom provocation using a standardized procedure performed by trained personnel. The patients are then assessed on D42 and D102 (i.e. 1 month and 3 months after the end of the tDCS sessions).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 24, 2023
CompletedFirst Posted
Study publicly available on registry
August 30, 2023
CompletedStudy Start
First participant enrolled
October 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
June 5, 2025
June 1, 2025
3.5 years
August 24, 2023
June 3, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
YBOCS scale
The primary endpoint corresponds to the change in the score on the YBOCS scale between the inclusion visit (Day 0) and the Day 42 visit. A score of 0 corresponds to the absence of OCD and a score of 40 to maximum severity.
3,5 months
Study Arms (1)
tDCS + symptoms provocation
EXPERIMENTALInterventions
The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
Eligibility Criteria
You may qualify if:
- Patient suffering from OCD evolving for at least 2 years diagnosed according to DSM-V criteria;
- Patient with good insight, defined by a score less than or equal to 18 at the threshold of delusions on the BABS (Brown Assessment of Beliefs Scale) insight scale;
- Absence of a current depressive episode (MADRS score \< 21) or suicidal risk (MADRS score item 10 \< 3);
- Absence of epileptic pathology;
- Chronic obsessive-compulsive disorder defined by a total YBOCS score \> 20, or a subscale score \> 15;
- Drug-resistant obsessive-compulsive disorder despite treatment with:
- at least 2 antidepressants of the IRS type at an effective dose and for a sufficient duration
- and/or Behavioral and Cognitive therapy for at least 1 year;
- Therapeutic stability (antidepressants) for more than 12 weeks without significant improvement. This treatment, at a fixed dose, will be maintained during the study;
- Patient aged between 18 and 70 included
- Patient who has given his/her informed consent after having received written information on the planned procedure;
- Patient benefiting from social security or by benefiting through a third party.
You may not qualify if:
- Woman of childbearing age without effective means of contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
- Pregnant or nursing woman;
- Patient hospitalized under duress (SPDT, SPDRE);
- Patient under guardianship or curatorship;
- Patient with another DSM-V Axis 1 diagnosis (Schizophrenic Disorder, Bipolar Disorder, Substance Abuse or Substance Dependence).
- Patient suffering from a current depressive episode;
- Patient at risk of suicide;
- Patient with skin lesions on the scalp;
- History of head trauma;
- Patient with an intracerebral metal object
- Patient with a pacemaker;
- Presence of epileptic pathology;
- Patient in an emergency situation or unable to give personal consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Hospitalier Henri Laborit
Poitiers, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 24, 2023
First Posted
August 30, 2023
Study Start
October 17, 2023
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
July 1, 2027
Last Updated
June 5, 2025
Record last verified: 2025-06